Thus, both pembrolizumab (PD-L1 CPS ≥ 10) and nivolumab (PD-L1 CPS agnostic) are IO options for second-line therapy in ESCC patients. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.